A research blog from the NCI Division of Cancer Prevention Subscribe The NCI Cancer Prevention Fellowship Program – Developing Multidisciplinary Scientists and Expanding the Cancer Prevention Workforce December 5, 2024 | By Jessica Faupel-Badger, Ph.D., M.P.H. & Alyssa Voss, M.P.H. The Cancer Prevention Fellowship Program (CPFP), NCI’s distinctive postdoctoral fellowship program that combines independent, mentored research with training in translational cancer prevention science, population health, leadership, and communication, is nearing its 40th anniversary. In light of this milestone, the CPFP, led by Acting Director, Jessica Faupel-Badger, Ph.D., M.P.H., took the opportunity to re-connect with program alumni across the globe and evaluate long-term outcomes of the program. A Deep Dive into Awareness and Perceptions of Potential Benefits and Harms of Multi-Cancer Detection Tests December 2, 2024 | By Goli Samimi, Ph.D., M.P.H. & Liz Freedman, M.S.W., M.P.H. Research is underway to try to address the many unanswered questions about cancer screening with multi-cancer detection (MCD) tests, a new type of blood test designed to detect multiple cancers. Targeting Prevention to Reduce the High Human Toll of Rare Cancers October 1, 2024 | By DCP Staff At the Rare Cancers Prevention and Interception workshop this year, cancer researchers from across the United States, Canada, and the United Kingdom and from across disciplines sought to address many of the issues that can hamper research progress for these diseases. Research Highlights: Looking Deep into Genetic Changes that Increase Colorectal Cancer Risk to Prevent or Detect Inherited Cancers September 10, 2024 | By DCP Staff Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common inherited genetic change that increases the risk of several kinds of cancer including colorectal cancer. About 3% of all colorectal cancers in the United States occur in people with these inherited genetic changes; more than 1 million people in the U.S. have this syndrome. Defining Patient Tolerability to Cancer Treatments Helps Reduce Negative Outcomes May 23, 2024 | By DCP Staff For decades, cancer patients have participated in clinical trials of new therapies, and clinicians have assessed and recorded any adverse or toxic reactions to the treatments. Over the years, researchers have standardized the reporting of those side effects using Common Terminology Criteria for Adverse Events (CTCAE). An Improved Prostate Cancer Biomarker Test May Help Men Avoid Unnecessary Biopsy April 29, 2024 | By Alyssa M. Voss, M.P.H. Researchers funded by NCI have developed and validated a new prostate cancer urinary biomarker test that can help differentiate who should proceed for biopsy after an elevated prostate-specific antigen (PSA) test from those who can wait. Cancer Pain Research Addressing Multiple Causes, Multiple Managements March 19, 2024 | By Rachel Altshuler, Ph.D., and Brennan Streck, Ph.D., R.N., M.P.H. As improved cancer treatments have led to increased cancer survivorship, cancer survivors are now living longer with chronic pain. NCI is supporting research to address this issue. Research Highlights: Barrett’s Esophagus Translational Research Network (BETRNet) Studies Provide Insights into Prevention and Risk for Esophageal Cancer January 30, 2024 | By Susan Jenks Findings from two studies aimed at learning more about preventing the type of esophageal cancer with the fastest growing incidence rate have emerged recently from the Barrett’s Esophagus Translational Research Network (BETRNet) as it winds down its collaborative activities. NCI Launches Network to Study Self-Collection for HPV Testing to Prevent Cervical Cancer January 25, 2024 | By DCP Staff On January 25, 2024, the National Cancer Institute (NCI), part of the National Institutes of Health, with public and private partners, is launching a new clinical trial network to gather data on a “self-collection” method of human papillomavirus (HPV) testing to prevent cervical cancer. This method, if determined viable, could open new opportunities for improving uptake of cervical cancer screening. Research Highlights: Investigating Ways to Reduce and Avoid Side Effects of Medications for Breast Cancer Risk Reduction December 15, 2023 | By DCP Staff There are many approved medications for reducing breast cancer risk, but they can cause toxic side effects that lead people to forego preventive interventions. Two recent NCI-supported studies looked at ways to provide breast cancer risk reduction while reducing the chance of adverse side effects. Pagination 1 2 3 4 … Next › Next page Last » Last page
